Impact of risk-reducing salpingo-oophorectomy in premenopausal women

References

• American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, 2013
   Google Scholar
• Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl) 2006;84:16–28
   PubMed Web of Science ®Google Scholar
• Sutcliffe S, Pharoah PD, Easton DF, Ponder BA. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. Int J Cancer 2000;87:110–17
   PubMed Web of Science ®Google Scholar
• Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329–33
   PubMed Web of Science ®Google Scholar
• Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20–6
   PubMed Web of Science ®Google Scholar
• van Driel CM, de Bock GH, Arts HJ, et al. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens. Maturitas 2015;80:318–22
   PubMed Web of Science ®Google Scholar
• Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–15
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–22
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117–30
   PubMed Web of Science ®Google Scholar
• Madalinska JB, van Beurden M, Bleiker EM, et al. Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J Clin Oncol 2007;25:301–7
   PubMed Web of Science ®Google Scholar
• Cohen JV, Chiel L, Boghossian L, et al. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer 2012;11:69–75
   PubMed Web of Science ®Google Scholar
• Madalinska JB, van Beurden M, Bleiker EM, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24:3576–82
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475–82
   PubMed Web of Science ®Google Scholar
• Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 2001;1:149–56
   PubMedGoogle Scholar
• Benshushan A, Rojansky N, Chaviv M, et al. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric 2009;12:404–9
   PubMed Web of Science ®Google Scholar
• Robson M, Hensley M, Barakat R, et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 2003;89:281–7
   PubMed Web of Science ®Google Scholar
• Michelsen TM, Dorum A, Trope CG, Fossa SD, Dahl AA. Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. Int J Gynecol Cancer 2009;19:1029–36
   PubMed Web of Science ®Google Scholar
• Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005;23:6890–8
   PubMed Web of Science ®Google Scholar
• Finch A, Metcalfe KA, Chiang J, et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 2013;22:212–19
   PubMed Web of Science ®Google Scholar
• Fang CY, Cherry C, Devarajan K, et al. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 2009;112:594–600
   PubMed Web of Science ®Google Scholar
• Bresser PJ, Seynaeve C, Van Gool AR, et al. The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. Eur J Cancer 2007;43:95–103
   PubMed Web of Science ®Google Scholar
• Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 2001;10:231–41
   PubMed Web of Science ®Google Scholar
• Heiniger L, Butow PN, Coll J, et al. Long-term outcomes of risk-reducing surgery in unaffected women at increased familial risk of breast and/or ovarian cancer. Fam Cancer 2015;14:105–15
   PubMed Web of Science ®Google Scholar
• Hallowell N, Baylock B, Heiniger L, et al. Looking different, feeling different: women's reactions to risk-reducing breast and ovarian surgery. Fam Cancer 2012;11:215–24
   PubMed Web of Science ®Google Scholar
• Pezaro C, James P, McKinley J, et al. The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause. Fam Cancer 2012;11:403–10
   PubMed Web of Science ®Google Scholar
• Johansen N, Liavaag AH, Tanbo TG, et al. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: impact of hormone replacement therapy. Gynecol Oncol 2016;140:101–16
   PubMed Web of Science ®Google Scholar
• Lorenz T, McGregor B, Swisher E. Relationship satisfaction predicts sexual activity following risk-reducing salpingo-oophorectomy. J Psychosom Obstet Gynaecol 2014;35:62–8
   PubMed Web of Science ®Google Scholar
• Tucker PE, Bulsara MK, Salfinger SG, et al. Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol Oncol 2016;140:95–100
   PubMed Web of Science ®Google Scholar
• Finch A, Metcalfe KA, Chiang JK, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011;121:163–8
   PubMed Web of Science ®Google Scholar
• Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–8
   PubMed Web of Science ®Google Scholar
• Michelsen TM, Dorum A, Dahl AA. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol Oncol 2009;113:128–33
   PubMed Web of Science ®Google Scholar
• Hooker GW, King L, Vanhusen L, et al. Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers. Hered Cancer Clin Pract 2014;12:9
   PubMed Web of Science ®Google Scholar
• Shigehiro M, Kita M, Takeuchi S, et al. Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report. Jpn J Clin Oncol 2016;46:254–9
   PubMed Web of Science ®Google Scholar
• Westin SN, Sun CC, Lu KH, et al. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 2011;117:2659–67
   PubMed Web of Science ®Google Scholar
• Challberg J, Ashcroft L, Lalloo F, et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 2011;105:22–7
   PubMed Web of Science ®Google Scholar
• Touboul C, Uzan C, Ichante JL, et al. Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer. Oncologist 2011;16:1250–7
   PubMed Web of Science ®Google Scholar
• Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause 2007;14:567–71
   PubMed Web of Science ®Google Scholar
• Fakkert IE, Abma EM, Westrik IG, et al. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. Eur J Cancer 2015;51:400–8
   PubMed Web of Science ®Google Scholar
• Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ. 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821–8
   PubMed Web of Science ®Google Scholar
• Chapman JS, Powell CB, McLennan J, et al. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol Oncol 2011;122:339–43
   PubMed Web of Science ®Google Scholar
• Garcia C, Lyon L, Conell C, Littell RD, Powell CB. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy. Gynecol Oncol 2015;138:723–6
   PubMed Web of Science ®Google Scholar
• Michelsen TM, Tonstad S, Pripp AH, Trope CG, Dorum A. Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. Int J Gynecol Cancer 2010;20:233–9
   PubMed Web of Science ®Google Scholar
• Michelsen TM, Pripp AH, Tonstad S, Trope CG, Dorum A. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer 2009;45:82–9
   PubMed Web of Science ®Google Scholar
• Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074–83
   PubMed Web of Science ®Google Scholar
• Rocca WA, Shuster LT, Grossardt BR, et al. Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Womens Health (Lond Engl) 2009;5:39–48
   PubMedGoogle Scholar
• Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361–7
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:7804–10
   PubMed Web of Science ®Google Scholar
• Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009;169:41–6
   PubMed Web of Science ®Google Scholar
• Loibl S, Schwedler K, von Minckwitz G, et al. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients-a double-blind, randomized study. Ann Oncol 2007;18:689–93
   PubMed Web of Science ®Google Scholar
• Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004;22:1045–54
   PubMed Web of Science ®Google Scholar
• Arts-de Jong M, Maas AH, Massuger LF, Hoogerbrugge N, de Hullu JA. BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. Crit Rev Oncol Hematol 2014;91:159–71
   PubMed Web of Science ®Google Scholar
• Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998;339:733–8
   PubMed Web of Science ®Google Scholar
• Hadjidakis D, Kokkinakis E, Sfakianakis M, Raptis SA. The type and time of menopause as decisive factors for bone mass changes. Eur J Clin Invest 1999;29:877–85
   PubMed Web of Science ®Google Scholar
• Melton LJ, 3rd., Khosla S, Malkasian GD, et al. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003;18:900–5
   PubMed Web of Science ®Google Scholar
• Yoshida T, Takahashi K, Yamatani H, Takata K, Kurachi H. Impact of surgical menopause on lipid and bone metabolism. Climacteric 2011;14:445–52
   PubMed Web of Science ®Google Scholar
• Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005;16:556–62
   PubMed Web of Science ®Google Scholar
• Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265–79
   PubMed Web of Science ®Google Scholar
• Franklin RM, Ploutz-Snyder L, Kanaley JA. Longitudinal changes in abdominal fat distribution with menopause. Metabolism 2009;58:311–15
   PubMed Web of Science ®Google Scholar
• Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009;54:2366–73
   PubMed Web of Science ®Google Scholar
• Nappi RE, Sinforiani E, Mauri M, et al. Memory functioning at menopause: impact of age in ovariectomized women. Gynecol Obstet Invest 1999;47:29–36
   PubMed Web of Science ®Google Scholar
• Farrag AK, Khedr EM, Abdel-Aleem H, Rageh TA. Effect of surgical menopause on cognitive functions. Dement Geriatr Cogn Disord 2002;13:193–8
   PubMed Web of Science ®Google Scholar
• Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345–57
   PubMed Web of Science ®Google Scholar
• Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651–62
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573–87
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–15
   PubMed Web of Science ®Google Scholar
• Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Panay N, Hamoda H, Arya R, et al. The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause Int 2013;19:59–68
   PubMedGoogle Scholar
• Reitsma W, de Bock GH, Oosterwijk JC, et al. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 2013;49:132–41
   PubMed Web of Science ®Google Scholar
• Leblanc E, Narducci F, Farre I, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol 2011;121:472–6
   PubMed Web of Science ®Google Scholar
• Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol 2014;133:283–6
   PubMed Web of Science ®Google Scholar